Weekly channel feed

A Penn spin­out goes dark; Thumbs down on ALS drug; TIG­IT runs in­to PhI­II flop; Sanofi's got big plans; and more

11 months ago

ALS drug sets the stage for fresh FDA de­bate; Im­plo­sions every­where you look; Big names turn up at biotechs; and more

12 months ago

Lat­est news on first-ever Lag-3 OK; Aduhelm sup­port, crit­i­cism both crescen­do; Phar­ma gets firm about Rus­sia; Set­backs mar top R&D prospects; and more

Last year

Re­vamp com­ing at Gilead; Lat­est from in Ukraine, Rus­sia; Bio­gen’s hang­ing bud­get ax; No­var­tis places gene ther­a­py bet; and more

Last year

The Pfiz­er pa­pers; Bio­gen lay­offs be­gin; Ab­b­Vie inks a buy­out; GSK makes Slaoui pay; and more

Last year

Lat­est news on J&J's ma­jor court win; Ukraine's place in biotech; Man­ag­ing ex­pec­ta­tions for AI; Lil­ly ups its RNA game; and more

Last year

In­side PBM­s' tac­tics to tilt the mar­ket; Is the KRAS race still on? CAR-T safe­ty scares trig­ger halts; and more

Last year

Lat­est news on Covid vac­cine de­lay for kids; Door slammed shut for Chi­na-on­ly da­ta; Er­ic Lan­der is out; Look­ing back at the boom; and more

Last year

R&D heads play phar­ma mu­si­cal chairs; Shat­tered block­buster dreams; Death of Aduhelm?; and more

Last year

'Thor­ough­ly f*****d' for cy­ber­at­tacks?; Bad week for drug de­vel­op­ers; The next big I/O break­through?; Bio­gen does a deal; and more

Last year

What lured Hal Bar­ron away?; Top FDA minds on ac­cel­er­at­ed ap­proval re­forms; ‘Dead wrong’ Aduhelm ad blitz; and more

Last year

Lat­est news on Pfiz­er's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the num­bers; Bio­gen's Aduhelm reck­on­ing; The sto­ry of sotro­vimab; and more

Last year

Three AI deals kick off #JPM22 week­end; Can Sil­i­con Val­ley change how sci­ence gets fund­ed?; Spe­cial re­port: 2021 new drug ap­provals; and more

Last year

It’s be­gin­ning to look a lot like M&A sea­son; Aduhelm runs in­to more re­sis­tance; Eli Lil­ly, Bris­tol My­ers get in ear­ly on can­cer ef­forts; and more

Last year

End­points hon­ors 20 women su­per­charg­ing drug R&D; Omi­cron is a 'stress test' for the next pan­dem­ic; Roche and Genen­tech strike an AI pact with Re­cur­sion; and more

Last year

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Last year

Thanks­giv­ing edi­tion: Top 15 End­points sto­ries of 2021; Can you name that vac­cine?; Mer­ck­'s Covid an­tivi­ral dis­ap­points; FDA nom­i­nee's in­dus­try ties; and more

Last year

Bio­gen’s no good week; In­side gene edit­ing's open se­cret; No­vo Nordisk ab­sorbs RNAi part­ner; Boost­ers for all; and more

Last year

J&J's im­pend­ing split; And the next FDA com­mish is...; Aduhelm back in spot­light; #AHA21; and more

Last year

Pfiz­er's Covid pill de­liv­ers; All you need to know about Dem­s' drug pric­ing plan; What else can an­ti­sense do?; and more

Last year

Lat­est news on Covid vac­cine OK; No­var­tis' 1 win and 1 flop; Eli Lil­ly and the Alzheimer's puz­zle; End of an era for Al­ny­lam; and more

Last year

So — that pig-to-hu­man trans­plant; Po­ten­tial di­a­betes cure reach­es pa­tient; Ac­cused MIT sci­en­tist lash­es back; and more

Last year

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Last year

Lat­est news: An­oth­er Alzheimer's 'break­through'?; GSK de­camps from icon­ic HQ; Red light in off-the-shelf CAR-T; Chart­ing biotech's Q3; and more

Last year
First page Previous page 12345 Next page Last page

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW
Subscribe to Endpoints News